Antagen Biosesciences, Inc. is a biotechnological company dedicated to providing biomedical and biotechnical services and products to biotech industry and biomedical community. Its multi-platform laboratory science capabilities, and top-notch systems and procedures also give the company a much-needed edge in the CRO/CMO market and innovative product development.
Antagen Biosesciences’ reputation and stability are grounded in the success of its fast-track and high-efficiency protein/Antibody mammalian cell expression system, high-efficiency Fut8-/- CHO cell expression system and antibody development. The expression systems stand out from others through its optimized combination of powerful expression vectors, rapid generation of high-yield stable CHO cell lines, and high-efficiency purification system. With the expression system, Antagen offers rapid and comprehensive services for production of recombinant proteins, wild-type antibodies and fucose-free antibodies worldwide, which is expected to put the company in an advantageous position in the global market of biologics production.
As a rapidly growing company, Antagen Biosesciences are driven by a management team with diverse expertise and experience, including R&D, process development, drug formulation, and business development. It is located in Boston area, one of the most fertile biotechnology and biopharmaceutical areas in the world.
From the test tube to the patient, we are looking at new, inventive ways to move our product candidates efficiently through the development process in an effort to get new products into the clinic.
At Antagen, we have recombinant protein based vaccines in preclinical development. The vaccines target influenza, rabies, and HPV infection in Asian populations as well as the U.S. population.
We have developed High-Performance mammalian cell lines expressing human serum albumin, second-generation Erythropoietin (EPO), and anti-rabies antibodies. We are seeking partnership with potential investors or pharmaceutical companies to commercialize these biological products.
We are in an early development stage of drugs targeting autoimmune diseases, cancer, Age-Related Macular Degeneration and Diabetes-Associated Retinal Atrophy.
Biologics Production in Global Demand
Biologics are one key growth driver in pharmaceutical and biotechnology industries. The global market for biologics or biotechnology drugs increased to $87 billion in 2008. By 2010, the global annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules. A booming necessity for biologics in the drug market is driving the global demand for biologics manufacturing capacity.
Antagen Technology — Protein Expression System
Antagen has pioneered the biologics production through its innovative fast-track and high-efficiency protein expression system. The expression system not only shortens the development time of stable cell lines to 2-3 months from traditional 6-12 months, but also increases the expression yield of target proteins more than two dozenfold.